If you have been reading about peptide research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-19. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
== Cancer research == Since the inception of phosphoproteomics, cancer research has focused on changes to the phosphoproteome during tumor development. Phosphoproteins could be cancer markers useful to cancer diagnostics and therapeutics. In fact, research has shown that there are distinct phosphotyrosine proteomes of breast and liver tumors. There is also evidence of hyperphosphorylation at tyrosine residues in breast tumors but not in normal tissues. Findings like these suggest that it is possible to mine the tumor phosphoproteome for potential biomarkers. Increasing amounts of data are available suggesting that distinctive phosphoproteins exist in various tumors and that phosphorylation profiling could be used to fingerprint cancers from different origins. In addition, systematic cataloguing of tumor-specific phosphoproteins in individual patients could reveal multiple causative players during cancer formation. By correlating this experimental data to clinical data such as drug response and disease outcome, potential cancer markers could be identified for diagnosis, prognosis, prediction of drug response, and potential drug targets.
== Early career == After graduating from MIT, Swanson took a job at Citibank, where he managed a venture investment group. His performance pleased his supervisors, and he and a colleague were chosen to open a San Francisco office for Citicorp Venture Capital. However, the new Citicorp investments were not doing well. One particular failure, which Swanson later believed to have been a lucky break, was the bankruptcy of Antex, a science based company that Citicorp had invested in. He worked with Eugene Kleiner, another Citicorp executive, to attempt to get some money out of the company's bankruptcy. Eugene Kleiner was the cofounder of the venture capital partnership Kleiner & Perkins. Swanson left Citicorp and joined Kleiner & Perkins in 1974, under the recommendation of Eugene Kleiner himself. As an associate, Swanson spent a lot of time and effort attempting to convince the heads of the science company Cetus, one which Kleiner and Perkins had invested in, to pursue genetic recombination projects. His interest in the technology had been piqued in a lunch with famed scientist and Nobel laureate Donald Glaser. However, the company refused to take on such a risky endeavor, and Kleiner & Perkins parted ways with the company. This falling out was one of the main reasons for the group's decision to advise Swanson to look for another job. Kleiner & Perkins had decided that they would rather work alone, and by the end of 1975, Swanson's position there would be terminated.
== History == Ketoconazole was discovered in 1976 at Janssen Pharmaceuticals. It was patented in 1977, followed by introduction in the United States in July 1981. Following its introduction, ketoconazole was the only systemic antifungal available for almost a decade. Ketoconazole was introduced as the prototypical medication of the imidazole group of antifungals. Oral ketoconazole has been replaced with oral fluconazole or itraconazole for many mycoses. Due to incidence of serious liver toxicity, the use of oral ketoconazole was suspended in France in July 2011, following review. This event triggered an evaluation of oral ketoconazole throughout the rest of the European Union. In 2013, oral ketoconazole was withdrawn in the European Union and Australia, and strict restrictions were placed on the use of oral ketoconazole in the United States and Canada. Oral ketoconazole is indicated for use in these countries when the indication is a severe or life-threatening systemic infection and alternatives are unavailable. However, topical ketoconazole, which does not distribute systemically, is safe and widely used still. Ketoconazole HRA was approved for use in the European Union for treatment of Cushing's syndrome in November 2013.
On April 12, 2023, it was announced that Cold Cave will tour in support of Depeche Mode's "Memento Mori" World Tour and will be at the following European dates and cities: May 16 & 18 in Amsterdam, Netherlands. May 20 in Antwerp, Belgium. May 23 in Stockholm, Sweden. May 26 in Leipzig, Germany. May 28 in Bratislava, Slovakia. In March 2025, the band was featured on vocals on a track called "So Then..." on a new album released by Chris Liebing.
Sources: en.wikipedia.org
=== Similar diseases with overlapping symptoms === Bullous Pemphigoid, Cicatricial Pemphigoid, Drug Eruptions. Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita, Erythema Multiforme, Lichen Planus, pemphigus vulgaris, Stevens–Johnson syndrome and toxic epidermal necrolysis. PNP is most commonly mistaken for pemphigus vulgaris, due to the extreme similarities of the lesions that develop. However, the difference lies in the specificity of the autoreactive antibodies in each case.
==== Meat ==== Unpreserved meat has only a relatively short storage life. Perishable meats should be refrigerated, frozen, dried promptly or cured. Storage of fresh meat is a complex discipline that affects cost, shelf life, and eating quality, and the appropriate techniques vary by meat type and specific requirements. For example, dry ageing techniques are sometimes used to tenderize gourmet meats by hanging them in carefully controlled environments for up to 21 days, while game animals of various kinds may be hung after shooting. Details depend on personal tastes and local traditions. Modern techniques of preparing meat for storage vary with the type of meat and special requirements of tenderness, flavor, hygiene, and economy. Semi-dried meats like salamis and country-style hams are first processed with salt, smoke, sugar, acid, or other "cures," then hung in cool, dry storage for extended periods, sometimes exceeding a year. Some of the materials added during the curing of meats serve to reduce the risks of food poisoning from anaerobic bacteria such as species of Clostridium that release botulinum toxin that can cause botulism. Typical ingredients of curing agents that inhibit anaerobic bacteria include nitrates.
Bio Products Laboratory Limited (BPL) is a company involved in the manufacture of human blood plasma products, located in Elstree, Hertfordshire, England. It is run as a commercial business and supplies plasma derived products to the National Health Service in the UK as well as to markets in over 45 countries. BPL was a state owned organization and it was part of the U.K. National Health Service for most of its existence. On 1 September 2022, Permira and the Marcucci family acquired BPL and announced that their operations will be merged with another company acquired by the duo, Kedrion.
=== Regulation by keap1/nrf2/are pathway === External (via chemicals) and internal (stress response or caloric restriction) induction of NQO1 is mediated solely through the Keap1/Nrf2/ARE. Keap1 acts as the sensor which loses its ability to target Nrf2 for degradation upon exposure to the inducers. Nrf2 is consequently stabilized and accumulated in the nucleus upon which it binds to the AREs and initiates expression of cytoprotective genes including NQO1.
High-Throughput Protein Laboratory for protein engineering Protein Purification Facilities for small- and large-scale protein production Macromolecular Crystallization & Crystallography Laboratories for solving crystal structures of biological molecules On-site X-ray facility Access to high energy synchrotron radiation at Argonne National Laboratory through the Life Science Collaborative Access Team (LS-CAT)
Sources: en.wikipedia.org
This bluebottle fly can also cause human or animal myiasis (parasitization in a living individual). Forensic scientists sometimes identify it in the course of their work, such as in one case of an autopsy of a neglected child.
== Disorders of thyroid gland (240–246) == 240 Simple and unspecified goiter 240.9 Goiter, unspec. 241 Nontoxic nodular goiter 241.0 Thyroid nodule 241.9 Goiter, unspec. nontoxic nodular 242 Thyrotoxicosis with or without goiter 242.0 Goiter toxic, diffuse 242.9 Hyperthyroidism, NOS 243 Congenital hypothyroidism 244 Acquired hypothyroidism 244.0 Hypothyroidism, post-surgical 244.1 Hypothyroidism, post-ablative 244.9 Hypothyroidism, unspec. 245 Thyroiditis 245.0 Thyroiditis, acute 245.1 Thyroiditis, subacute 245.2 Thyroiditis, chronic, Hashimoto's 246 Other disorders of thyroid 246.2 Thyroid cyst
==== Superficial vein thrombosis ==== SVT is the development of a thrombus in a superficial vein. SVT is not normally clinically significant, but the thrombus can migrate into the deep venous system where it can also give rise to a pulmonary embolism. The main risk factor for SVT in the lower limbs is varicose veins.
Similarly, a pure soul is part of this world, yet is not of this world, much like the circumstances of the lotus. The poem further emphasizes the importance of true knowledge or gnosis, which is likened to the pure rainwater that allows the lotus to flourish. Ismaili belief holds that the true guide provides this true knowledge, without which the pure soul cannot survive. Just as the lotus flower would rather die than drink from a reeking swamp, the pure soul also seeks nourishment solely through true knowledge. In Chinese culture, the lotus is known as "Liánhuā" (蓮花) and holds important cultural significance in Chinese Buddhism, symbolizing purity, enlightenment, and the unfolding of the spiritual self. In Neo-Confucianism, the lotus is regarded as a symbol of Junzi or noble character, according to the Song dynasty scholar Zhou Dunyi.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.